Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System

Trial Profile

A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2018

At a glance

  • Drugs Aspirin (Primary) ; Clopidogrel (Primary) ; Everolimus (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary)
  • Indications Coronary artery restenosis; Coronary stent thrombosis; Thrombosis
  • Focus Adverse reactions
  • Acronyms EVOLVE Short DAPT
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 25 Sep 2018 Baseline characteristics of this trial presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics. 3-month clinical outcomes will be available at the time of presentation.
    • 20 Sep 2018 New trial record
    • 17 Aug 2018 Rationale and trial design data published in the American Heart Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top